Skip to main content
Clinical Trials/EUCTR2008-003690-40-IT
EUCTR2008-003690-40-IT
Active, not recruiting
Not Applicable

ow-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 sitesJuly 30, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
advanced and/or metastatic NSCLC
Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 30, 2008
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Eligibility Criteria

Inclusion Criteria

  • histologic or cytologic confirmation of NSCLC
  • measurable disease
  • PS \= ECOG 0\-2
  • WBC ≥3500 e PLT ≥ 100\.000
  • adequate bone marrow, renal, and hepatic function.
  • written informed consent before treatment
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • prior chemotherapy with pemetrexed
  • autoimmune disease interfering with radiotherapy
  • other concomitant neoplasm
  • mentally disturbed patients with low compliance to treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with limited metastatic disease - TNT-OES-1 TRIA
NL-OMON49762Erasmus MC, Universitair Medisch Centrum Rotterdam20
Recruiting
Not Applicable
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
NL-OMON23939Erasmus MC20
Active, not recruiting
Phase 1
Chemotherapy followed by chemoradiotherapy for metastatic esophageal cancerPatients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-003605-55-NLErasmus MC - University Medical Centre20
Unknown
Phase 3
A comparison of concurrent chemo-radiotherapy plus hyperthermia versus concurrent chemo-radiotherapy in locally advanced cervical cancer patients: A randomized controlled trial&#45This study aim to compare concurrent chemoradiotherapy and concurrent chemoradiotherapy plus hyperthermia in locally advanced cervical cancer in term of treatment response rate.Deep regional hyperthermiaThermotron&#45RF8radiation therapychemotherapy
TCTR20180711002Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy90
Recruiting
Not Applicable
Clinical trial of concurrent chemoradiotherapy (CCRT) with S-1 in patients with advanced head and neck squamous cell carcinoma, who is not eligible for CCRT with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) regimeadvanced head and neck squamous cell carcinoma
JPRN-UMIN000021870Yokohama City University hospital40